Is INCAF or JNJ a better dividend investment in 2026?

INCAF currently yields 2877.70% with a 5% 5-year dividend growth rate. JNJ yields 2.13% with 5.8% growth. The better choice depends on your goal: INCAF offers higher current income.

What is the dividend yield difference between INCAF and JNJ?

INCAF has a forward dividend yield of 2877.70% ($2.00/share annually). JNJ yields 2.13% ($5.20/share annually). The yield gap is 2875.57 percentage points.

Home › Compare › INCAF vs JNJ

INCAF vs JNJ: Dividend Comparison 2026

INCAF yields 2877.70% · JNJ yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 INCAF wins by $305883585404.78M in total portfolio value

INVESTMENT

TIME HORIZON10 years

INCAF

● Live price

2877.70%

Share price

$0.07

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$305883585404.81M

Annual income

$286,311,741,458,861,220.00

Full INCAF calculator →

JNJ

Johnson & Johnson

● Live price

2.13%

Share price

$244.44

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.3K

Annual income

$4,689.40

Full JNJ calculator →

Portfolio growth — INCAF vs JNJ

📍 INCAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	INCAF	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, INCAF + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

INCAF pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INCAF

Annual income on $10K today (after 15% tax)

$244,604.32/yr

After 10yr DRIP, annual income (after tax)

$243,364,980,240,032,030.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$180.82/yr

After 10yr DRIP, annual income (after tax)

$3,985.99/yr

At 15% tax rate, INCAF beats the other by $243,364,980,240,028,030.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INCAF + JNJ for your $10,000?

INCAF: 50%JNJ: 50%

100% JNJ50/50100% INCAF

Portfolio after 10yr

$152941792702.42M

Annual income

$143,155,870,729,432,960.00/yr

Blended yield

93.60%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

INCAF

No analyst data

Altman Z

-1.8

Piotroski

2/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-6.4% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INCAF buys

JNJ buys

No recent congressional trades found for INCAF or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricINCAFJNJ

Forward yield	2877.70% ✓	2.13%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$305883585404.81M ✓	$30.3K
Annual income after 10y	$286,311,741,458,861,220.00 ✓	$4,689.40
Total dividends collected	$304527346519.57M ✓	$15.4K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: INCAF vs JNJ ($10,000, DRIP)

Year	INCAF Portfolio	INCAF Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$298,470	$287,769.78	$10,592	$272.30	+$287.9K → INCAF
2	$8,346,520	$8,027,157.51	$11,289	$357.73	+$8.34M → INCAF
3	$218,719,956	$209,789,179.05	$12,123	$472.89	+$218.71M → INCAF
4	$5,371,890,365	$5,137,860,012.28	$13,141	$629.86	+$5371.88M → INCAF
5	$123,681,431,725	$117,933,509,034.97	$14,408	$846.81	+$123681.42M → INCAF
6	$2,669,983,778,821	$2,537,644,646,875.06	$16,021	$1,151.60	+$2669983.76M → INCAF
7	$54,054,664,765,172	$51,197,782,121,833.21	$18,122	$1,588.22	+$54054664.75M → INCAF
8	$1,026,544,348,282,010	$968,705,856,983,276.40	$20,930	$2,228.20	+$1026544348.26M → INCAF
9	$18,291,442,940,141,270	$17,193,040,487,479,522.00	$24,792	$3,191.91	+$18291442940.12M → INCAF
10	$305,883,585,404,812,350	$286,311,741,458,861,220.00	$30,274	$4,689.40	+$305883585404.78M → INCAF

INCAF vs JNJ: Complete Analysis 2026

INCAF — Stock

Inca One Gold Corp. engages in the business of operating and developing of gold-bearing mineral processing operations in Peru. It holds 100% interests in the Chala One property located in Peru. The company also holds 90.14% interests in the Kori One property in Peru. The company was formerly known as Inca One Resources Corp. and changed its name to Inca One Gold Corp. in September 2014. Inca One Gold Corp. was incorporated in 2005 and is headquartered in Vancouver, Canada.

Full INCAF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this INCAF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INCAF vs SCHD INCAF vs JEPI INCAF vs O INCAF vs KO INCAF vs MAIN INCAF vs ABBV INCAF vs MRK INCAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.